Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RJMty19 in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT06314828Phase 1Not yet recruiting
- Sponsor
- Guangdong Ruishun Biotechnology Co., Ltd.
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of RJMty19 in B-cell non-Hodgkin lymphoma, sponsored by Guangdong Ruishun Biotechnology Co., Ltd. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Planned start May 2024; status: not yet recruiting.
02
Drugs
RJMty19
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06314828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06314828.